AKT1 and pancreatic neoplasm: These studies provided a foundation upon which to further examine the role of aplysin in cancer therapy, particularly applicable in diseases where PI3K/AKT is known to be the oncogenic driver, including breast, colon, ovarian, prostate and pancreatic cancers.